DMD.
ANP could be on a winner.Big $ to be made .Bio Marin paid $680 mill for a unproven drug.
BioMarin gambled $680 million in cash when it decided to buy Prosensa and its failed DMD drug drisapersen and make a bid to revive its prospects at the FDA. That effort was hit head on by the FDA’s rejection in early 2016. If BioMarin chooses to go for another exon-skipping drug, the company has rights to opt in on a co-exclusive deal with Sarepta...
ANP have enlisted a Board of international experts in DMD.......So Atl 1102 must have merit in the treatment for DMD.
The clinical trial of ATL1102 is planned to be undertaken at the Royal Children’s Hospital (RCH) in Melbourne, with the clinical development of ATL1102 in boys with DMD to be directed by an Advisory Board of international experts in the field. The Advisory Board is chaired by Mr William Goolsbee, a non-executive director of ANP and ex-Chairman of Sarepta Therapeutics (Sarepta are marketers of the antisense drug, eteplirsen, the first and only drug approved for the restoration of muscle dystrophin). Membership of the Advisory Board includes the Australian inventors of eteplirsen, Professor Steve Wilton and Professor Sue Fletcher (from Perth’s Western Australian Neuroscience Research Institute and Murdoch University respectively), and Dr Gillian Butler-Browne, Director, Centre of Research in Myology at Sorbonne University in Paris (whose team observed that circulating high CD49d expressing T- cells lead to poor prognosis in DMD patients).
ANP Price at posting:
3.7¢ Sentiment: Buy Disclosure: Held
